PCRX : Insider Transactions for Pacira Pharmaceuticals, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Pacira Pharmaceuticals, Inc. (PCRX)

$29.07 0.00 (0.00%) as of 4:30 Mon 5/13

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

32,553,000 as of 6/30

Market Cap:

946.32(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$10.15 - $30.08

Level I Sector:

Health Care

Level II Sector:

Drugs

Level III Sector:

Drug Manufacturers - Major

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : -

Guru Rank Value : -

Guru Occurances : -


6 Months 1 Year 2 Year

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Company Profile Pacira Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Co.'s main product candidate is EXPAREL, a bupivacaine (anesthetic/analgesic) product for postsurgical pain management. Co.'s marketed products and their respective indication are DepoCyt(e) for lymphomatous meningitis; and DepoDur for post-operative pain; while its preclinical products and their respective indication are DepoNSAID for acute pain and DepoMethotrexate for rheumatoid arthritis oncology.

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	853	853	853	3,635,685
Total Buy Value	$24,993	$24,993	$24,993	$24,487,472
Total People Bought	1	1	1	9
Total Buy Transactions	1	1	1	12
Total Shares Sold	5,873,147	6,873,147	6,873,147	7,256,088
Total Sell Value	$159,127,559	$178,057,559	$178,057,559	$182,223,500
Total People Sold	13	13	13	14
Total Sell Transactions	40	42	42	51
End Date	2013-02-19	2012-11-18	2012-05-20	2011-05-21

Adjust Filter Settings

Records found: 116

Page 1 of 5

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Hastings Paul J

Director

– • –

2013-05-15

4

B

$29.30

$24,993

D/D

853

853

2.39

-0%

Director

– • –

2013-04-24

4

AS

$30.04

$12,045

I/I

(401)

2,176,652

-0%

Director

– • –

2013-04-24

4

AS

$30.04

$189,342

I/I

(6,303)

1,163,486

-0%

Director

– • –

2013-04-23

4

AS

$30.00

$469,380

I/I

(15,646)

2,177,053

-0%

Director

– • –

2013-04-23

4

AS

$30.00

$3,243,450

I/I

(108,115)

1,169,789

-0%

Director

– • –

2013-04-15

4

AS

$30.00

$77,250

I/I

(2,575)

1,277,904

1%

Director

– • –

2013-04-15

4

AS

$30.00

$192,020

I/I

(6,400)

2,192,699

1%

Chief Medical Officer

• – –

2013-04-12

4

OE

$1.61

$16,100

D/D

10,000

10,000

-

Director

– • –

2013-04-12

4

AS

$30.00

$1,028,820

I/I

(34,294)

2,199,099

-3%

Chief Medical Officer

• – –

2013-04-12

4

AS

$30.00

$300,000

D/D

(10,000)

0

-3%

Director

– • –

2013-04-12

4

AS

$30.00

$300,000

I/I

(10,000)

1,280,479

-3%

Director

– • –

2013-04-12

4

S

$29.30

$100,089

I/I

(3,416)

1,314,255

3%

Director

– • –

2013-04-12

4

OE

$2.69

$100,046

I/I

37,192

1,317,671

-

Director

– • –

2013-04-11

4

AS

$30.00

$18,000

I/I

(600)

2,233,393

-0%

Chief Medical Officer

• – –

2013-04-01

4

AS

$27.75

$844,591

D/D

(30,000)

0

2%

Chief Medical Officer

• – –

2013-04-01

4

OE

$1.61

$48,300

D/D

30,000

30,000

-

Scibetta James S

Chief Financial Officer

• – –

2013-03-28

4

OE

$1.61

$16,100

D/D

10,000

15,000

-

Scibetta James S

Chief Financial Officer

• – –

2013-03-28

4

AS

$28.49

$284,900

D/D

(10,000)

5,000

1%

President and CEO

• • –

2013-03-28

4

OE

$1.61

$24,150

D/D

15,000

17,573

-

President and CEO

• • –

2013-03-28

4

AS

$28.66

$429,900

D/D

(15,000)

2,573

1%

Longenecker John P Phd

Director

– • –

2013-03-28

4

OE

$1.61

$3,220

D/D

2,000

2,000

-

Longenecker John P Phd

Director

– • –

2013-03-28

4

AS

$28.49

$56,980

D/D

(2,000)

0

1%

Hbm Bioventures Cayman Ltd

10% Owner

– – •

2013-03-25

4

AS

$28.28

$4,680,738

D/D

(165,541)

2,233,993

3%

Director

– • –

2013-03-25

4

AS

$28.28

$4,680,738

I/I

(165,541)

2,233,993

3%

Director

– • –

2013-03-22

4

AS

$27.52

$3,135,595

I/I

(113,928)

2,399,534

6%

116 Records found	1 2 3 4 5	Page 1 of 5

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2010 J3SG.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.